A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens

Urological Research

Volumn 28, Issue 3, 2000, Pages 201-209

  Levin, R M ^a   Das, A K ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Bladder; BPH; Prostate; Pygeum africanum; Serenoa repens

Indexed keywords

PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT;

ARTICLE; BLADDER FUNCTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG QUALITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MALE; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY;

ANDROGEN ANTAGONISTS; ANIMALS; FATTY ALCOHOLS; GROWTH INHIBITORS; HUMANS; MALE; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; SERENOA;

EID: 0033919056     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002409900098     Document Type: Article

References (88)

1. Buck AC (1996) Phytotherapy for the prostate. Br J Urol 78: 325-336
2. Lowe FC, Dreikom K, Borkowski A, Braeckman J, Denis L. Ferrari P. Gerber G, Levin R, Perrin P, Senge T (1998) Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate 37: 187-193
3. Fitspatrick JM, Braeckman J, Denis L, Dreikorn K, Khoury S, Levin R, Perrin P (1996) The Medical Management of BPH with agents other than hormones or alpha-blockers. In: Cockett, Khoury, Chatelain, Denis, Griffrths, Murphy (eds) Proceedings from the 3rd International Consultation on Benign Prostatic Hyperplasia (Eds.). Scientific Communications, pp 489-494
4. Dreikorn K, Borkowski J, Braeckman J, Denis L, Gerber G, Levin R, Lowe F, Perrin P, Senge T (1983) Other medical therapies. In: Denis, Griffiths, Khoury, Cockett, McConnell, Chatelain, Murphy, Yoshida(eds) Proceedings from the 4th International Consultation on Benign Prostatic Hyperplasia). Scientific Communications pp 635-659
5. Sterling AM, Ritter RC, Zinner NR (The physical basis of obstructive uropathy). In: Benign prostatic hypertrophy. Springer, Berlin Heidelberg New York, pp 433-442
6. Grayhack JT, Kozlowski JM (1987) Benign prostatic hyperplasia. In: Gillenwater JY, Grayhack JT, Howards SS, Duckett JW (eds.) Adult and pediatric urology. Year Book, Chicago, pp 1062-1126
7. Steers WD, Barrett DM, Wein AJ (1996) Voiding dysfunction: diagnosis, classification and management. In: Gillenwater JY, Grayhack JT, Howards SS, Duckett JW (eds.) Adult and pediatric urology, 3rd edn. Year Book, Chicago, pp 1220-1325
8. Levin RM, Haugaard N, O'Connor L, Buttyan R, Das AK, Dixon JS, Gosling JA Obstructive response of human bladder to BPH vs., rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn (in press)
9. Kojima M, Inui E, Ochiai A, Naya Y, Ukimura O. Watanabe H (1996) Ultrasonic estimation of bladder weight as a measure of bladder hypertrophy in men with infravesical obstruction: a preliminary report. Urology 47: 942-947
10. Manier C, Carte SS, Romano G, Trucchi A, Valent M, Tubaro A (1998) The diagnosis of bladder outlet obstruction in men by ultrasound measurement of bladder wall thickness. J Urol 159: 761-765
11. Gilpin SA, Gosling JA Barnard RJ (1985) Morphological and morphometric studies of the human obstructed, trabeculated urinary bladder. Br J Urol 57: 525-529
12. Gosling JA Dixon JS (1980) Structure of trabeculated detrusor smooth muscle in cases of prostatic hypertrophy. Urol Int 35: 351-355
13. Ichiyanagi, O. Nakada T (1997) Correlations between parameters in pressure-flow analysis and histological compositions in prostate in patients with benign prostatic hyperplasia. Urol Int 59(3): 154-160
14. Terris MK, Afzal N, Kabalin JN (1998) Correlation of transrectal ultrasound measurements of prostate and transition zone size with symptom score, bother score. urinary flow rate, and post-void residual volume. Urology 52(3): 462-466
15. Wein AJ, Longhurst PA, Levin RM (1994) Pharmacologic treatment of voiding dysfunction. In: Mundy AR. Stephenson TP, Wein AJ (eds) Urodynamics: principles, practice, and application. Churchill Livingstone, New York, pp 43-70
16. Holtgrewe HL (1998) Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia. Urology 51: 1-7
17. Olsson GP, Hermamr D, Hammarlund-Udenaes M, Karlsson MO (1999) Validation of a population pharmacokinetic/pharmacodynamic model for 5alpha-reductase inhibitors. Eur J Pharmacol 8: 291-299
18. Weisser H, Krieg M (1998) In vitro inhibition of androstenedione 5alpha-reduction by finasteride in epithelium and stroma of human benign prostatic hyperplasia. J Steroid Biochem Mol Biol 67: 49-55
19. Barlet A, Albrecht J, Aubert A, Fischer M, Grof F, Grothuesmann HG, Masson J-C, Mazeman E, Mermon R, Reichelt H, Schonmetzler F, Suhler A (199O) Efficacy of Pygeum africanum extract in the treatment of micturitional disorders due to benign prostatic hyperplasia: evaluation of objective and subjective parameters: a multicentre, placebo-controlled double-blind trial. Wien Klin Wochenschr 232
20. Breza J, Dzurny O, Borowka A, Hanus T, Petrik R, Blane G, Chadha-Boreham H (1998) Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. Curr Med Res Opin 14: 127-139
21. Carraro J C, Raynaud JP, Koch G, Chisholn GD, Di Silverio F, Teillac P, Calais da Silva F, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier Perrin P (1996) Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1098 patients. Prostate 29: 231-240
22. Descotes JL, Rambeaud JJ, Faure G (1996) Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 9: 291-297
23. Grasso M, Montesano A, Buonaguidi A, Castelli M, Lania C, Rigatti P, Rocco F, Cessna BM, Borghi C (1995) Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 48: 97-103
24. Iwamura M, Koshiba K, Cockett AT (1998) Receptors for BPH growth factors are located in some neuroendocrine cells. Prostate Suppl 8: 14-17
25. Desgrandchamps F (1997) Clinical relevance of growth factor antagonists in the treatment of benign prostatic hyperplasia. Eur Urol 32 [Suppl]: 28-31
26. Lawson RK (1997) Role of growth factors in benigriprostatic hyperplasia. Eur Urol 32 [Suppl]: 22-27
27. Yablonsky F, Nicolas V, Riffaud J-P, Bellamy F (1997) Antiproliferative effect of Pygeum africanum extract on rat prostatic tibroblasts. J Urol 157: 2381-2387
28. Chaudry AA, Wahle KW, McClinton S, Moffat LE (1994) Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 57: 176-180
29. Anim JT, Udo C, John B (1998) Characterisation of inflammatory cells in benign prostatic hyperplasia. Acta Histochem 100: 439-449
30. Paubert-Braquet M, Cave A, Hocquemiller R, Delacroix D, DuPont C, Hedef N (1994) Effect of Pygeum africanum extract on A23187-stimulated production of lipoxygenase metabolites from human polymorphonuclear cells. J Lipid Mediat Cell Signal 9: 285-290
31. Friek J, Aulitzky W (1991) Physiology of the prostate. Infection 19 [Suppl]: S115-118
32. Griffiths K, Eaton CL, Harper ME, Peeling B, Davies P (1991) Steroid hormones and the pathogenesis of benign prostatic hyperplasia. Eur Urol 20 [Suppl]: 68-77
33. Isaacs JT, Coffey DS (1989) Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 2: 33-50
34. Mathe G, Orbach-Arbouys S, Bizi E, Court B (1995) The socalled phyto-estrogenic action of Pygeum africanum extract. Biomed Pharmacother 49: 339-40
35. Mathe G, Hallard M, Bourut CH, Chenu EA (1995) Pygeum africanum extract with so-called phyto-estrogenic action markedly reduces the volume of true and large prostatic hypertrophy. Biomed Pharmacother 49: 341 343
36. Rhodes L, Primka RL, Berman C, Vergult G, Gabriel M, Pierre-Malice M, Gibelin B (1993) Comparison of finasteride (Proscar), a 5χ-reductase inhibitor, and various commercial plant extracts in vitro and in vivo 5χ-reductase inhibition. Prostate 22: 43-51
37. Hartmann RW, Mark M, Soldati F (1996) Inhibition of 5χ-reductase and aromatase by PHL-00801 (Prostatonin), a comnination of PY 102 (Pygeum africanum) and UR 102 (Urtica dioica) extracts. Phytomedicine 4: 121-128
38. Choo M-S, Constantine CE, Bellamy F (1999) Beneficial effects of Pugeum africanum extract on dihydrotestosterone induced modifications of micturition and prostate growth in rats (absract). J Urol 161 [Suppl]: 229
39. Steers WD (1992) Physiology of the urinary bladder. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr (eds) Cambell's urology. Saunders, Philadelphia, pp 142-176
40. Zderic SA, Levin RM, Wein AJ (1996) Voiding function and dysfunction: a relevant anatomy, physiology, and pharmacology, and molecular biology. In: Gillenwater JY, Grayhack JT, Howards SS, Duckett JD (eds) Adult and pediatric urology 3rd edn. Year Book, Chicago, pp 1159-1219
41. Levin RM, Longhurst PA, Monson FC, Kato K, Wein AJ (1990) Effect of bladder outlet obstruction on the morphology, physiology, and pharmacology of the bladder. Prostate [Suppl] 3: 9
42. Levin RM, Monson FC, Longhurst PA, Wein AJ (1994) The rabbit as a model of urinary bladder function. Neurourol Urodyn 13: 119-136
43. Levin RM, Monson FC, Haugaard, N, Buttyan R, Hudson A, Roelofs M, Sartore S, Wein AJ (1995) Genetic and cellular characteristics of bladder outlet obstruction. Urol Clin North Am 22: 263-283
44. Levin RM, Monson FC, Haugaard N, Buttyan R, Hudson A, Roelofs M, Sartore S, Wein AJ (1995) Genetic and cellular characteristics of bladder outlet obstruction. Adv Benign Prostate Hyperplasia 22: 263-283
45. 3H-thymidine uptake and metabolism: a radiographic and biochemical study. J Urol 148: 158-162
46. Monson FC, Wein AI, Eika B, Murphy M, Levin RM (1994) Stimulation of the proliferation of rabbit bladder urothelium by partial outlet obstruction and acute overdistension. Neurourol Urodyn 13: 51-62
47. Santarosa R, Colombel M, Kaplan S, Monson F, Levin R, Buttyan R (1994) Hyperplasia and apoptosis: opposing cellular forces that regulate the response of the rabbit bladder to transient outlet obstruction. Lab Invest, 70: 503-510
48. Levitt RM, Saito M, Wein AJ, Packard D, Cohen A, Haugaard M (1993) Effect of partial outlet obstruction on choline acetyltransferase activity in the rat and rabbit. Neurourol Urodyn 12: 255-262
49. Roelofs M, Wein AJ, Barasha B, Monson FC, Passerini-Glazel G, Koteliansky VE, Sartore S, Levin RM (1995) Contractility and phenotype transitions in serosal thickening of obstructed rabbit bladder. J Applied Physiol 78: 1432-1441
50. Zderic S, Rohrmann D, Gong C, Snyder HMcC, Duckett JW, Wem AJ, Levin RM (1996) The decompensated detrusor II: evidence for loss of sarcoplasmic reticulum function following bladder outlet obstruction in the rabbit. J Urol 156: 587-592
51. ++ ATP-ase in rabbit bladder muscle and mucosa: effect of urinary outlet obstruction. Neurorurol Urodyn 15: 555-561
52. Haugaard N, Potter L, Wein AJ, Levin RM (1992) Effect of partial obstruction of the rabbit urinary bladder on malate dehydrogenase and citrate synthase activity. J Urol 147: 1391-1393
53. Hsu TH-S, Levin RM, Wein AJ, Haugaard N (1994) Alterations of mitochondrial oxidative metabolism in rabbit urinary bladder after partial outlet obstruction. Mol Cell Biochem 141: 21-26
54. Kojima M, Inui E, Ochiai A, Naya Y, Ukimura O, Watanabe H (1996) Ultrasonic estimation of bladder weight as a measure of bladder hypertrophy in men with infravesical obstruction: preliminary report. Urology 47: 942-947
55. Harrison SCW, Hunnam GR, Farman P, Ferguson DR, Doyle PT (1987) Bladder instability and denervation in patients with bladder outflow obstruction. Br J Urol 60: 519-522
56. Gosling JA, Gilpin SA, Dixon JS, Gilpin CJ (1986) Decrease in the autonomie innervation of human detrusor muscle in outflow obstruction. J Urol 136: 501-540
57. Levin RM, Haugaard N, Mogavero L, Leggett RE, Das AK (1999) Biochemical evaluation of obstructive bladder dysfunctionin men secondary to BPH: a preliminary report. Urology 53: 446-450
58. Levin RM, Riffaud J-P, Bellamy D, Rohrmamr F, Habib M, Krasnopolsky L, Zhao Y, Wein AJ (1996) Protective effect of Tadenan on bladder function secondary to partial outlet obstruction. J Urol 155: 1466-1470
59. Levin RM, Riffaud J-P, Bellamy F, Rohrmann, D, Krasnopolsky L, Haugaard N, Zhao Y, Wein AJ (1996) Effects of Tadenan pretreatment on bladder physiology and biochemistry following partial outlet obstruction. J Urol 156: 2084-2088
60. Levin ARM, Das AK, Haugaard N, Novitsky Y, Horan P, Leggett, RE, Riffaud J-P, Longhurst, PA (1997) Beneficial effects of Tadenan therapy following two weeks of partial outlet obstruction in the rabbit. Neurourol Urodyn 16: 583-599
61. Chen M-W, Levin RM, Horan P, Buttyan R, (1999) Effect of Tadenan® on the expression of HSP-68 following partial outlet obstruction (abstract). J Urol 161 [Suppl]: 229
62. Gomes CM, DiSanto M, Hypolite JA, Horan P, Levin RM, Wein AJ, Chacko S (1999) Reversal of obstruction-induced bladder dysfunction by Tadenan treatment is correlated with a return to the composition of myosin isoform present in the normal detrusor smooth muscle. Proceedings from the 20th Annual Scientific Meeting of the Society for Urodynamics and Female Urology, p P29
63. Valentini FA, Besson GR, Nelson PP (1999) Modelized analysis of the effect of Tadenan (Pygeum africanum extract) on the bladder of patients with benign prostatic hyperplasia: Blind vs open study of uroflows. Proceedings from the 20th Annual Scientific Meeting of the Society for Urodynamics and Female Urology, p P2
64. Greenland JE, Hvistendahl JJ, Andersen H, Jorgensen TM, Constantinou CE, McMurray G (1997) Detrusor and kidney blood flow is reduced in response to early bladder outlet obstruction in pigs. J Urol 157: 172
65. Azadzoi KM, Pontari M, Vlachiotis J, Siroky MB (1996) Canine bladder blood flow and oxygenation: changes induced by tilling, contraction and outlet obstruction. J Urol 155: 1459-1465
66. Lin AT, Chen MT, Yang CH, Chang LS (1995) Blood flow of the urinary bladder: effects of outlet obstruction and correlation with bioenergetic metabolism. Neurourol Urodyn 14: 285-292
67. Zhao Y, Levin SS, Wein AJ, Levin RM (1997) Correlation of ischemia/reperfusion and partial outlet obstruction induced spectrin proteolysis by calpain with contractile dysfunction in the rabbit bladder. Urology 49: 293-300
68. Chen M-W, Levin RM, Horan P, Buttyan R (1999) Effects of unilateral ischemia on the contractile response of the bladder: protective effect of Tadenan. Mol Urol 3:5-10
69. Panne J, Marks LS, Pearson JD, Rittenhouse HG, Chart DW, Shety ED, Gormley GJ, Subong EN, Kelley CA, Stoner E, Partin AW (1998) Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol 159: 449-453
70. Marberger M (1998) Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 51: 677-686
71. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrbom CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med 338: 557-563
72. Bayne CW, Grant ES, Chapman K, Habib FK Characterisation of a new co-culture model for BPH which expresses 5 alpha-reductase types I and II: The effects of Permixon on DHT formation
73. Iele C, Delos S, Guirou O, Tate R, Raynaud J-P, Martin P-M (1995) Human prostatic steroid 5-reductase isoforms. A comparative study of selective inhibitors. J Steroid Biochem Mol Biol 54: 273
74. Weisser H, Tunn S, Behnke B, Krieg M (1996) Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-rductase activity in human benign prostatic hyperplasia. Prostate 28: 300-306
75. Delos S, Carsol JL, Ghazarossian E, Raynaud JP, Martin PM (1995) Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts. J Steroid Biochem Mol Biol 55: 375-383
76. Raynaud J-P, Cousse H, Martin P-M (1998) Selectivity of free fatty acids on 5χ-reductase inhibitory activity. J Urol 159 [Suppl]: 110
77. Bayne CW. Donnelly F, Ross M, Miller WR, Habib F (1999) Differential effects of the BPH drug Permixon on cells from-various tissues (abstact). J Urol 161 [Suppl]: 228
78. Wright AS. Thomas LN, Douglas RC, Lazier CB, Rittmaster RS (1996) Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest 98: 2558-2563
79. Paubert-Braquet M, Richardson FO, Servent-Saez N, Gordon WC, Monge M-C, Bazan NG, Authie D, Braquet P (1996) Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat. Pharmacol Res 34: 171-179
80. Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, D'Eramo G, Di Nicola S, Toscano V (1998) Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 37: 77-83
81. Vacherot F, Azzouz M, Gil-Diez-de Medina S, Raynaud JP, Abou CC, Chopin D (1999) Effect of Permixon on apoptosis and proliferation in the prostate of patients with BPH (abstract). J Urol 161 [Suppl]: 228
82. Paubert-Braquet M, Raynaud J-P, Braquet PG, Castres HC (1997) Permixon [lipid sterolic extract of serenoa repens (LSESr)] and some of its components inhibits b-FGF-and EGF-induced proliferation of human prostate organotypic cell lines. J Urol 157 [Suppl]: 138
83. Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta JM, Braquet P (1998) Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic tibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 33: 340-347
84. Paubert-Braquet M, Mencia, Huerta JM, Cousse H, Braquet P (1997) Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids 57: 299-304
85. Mitropoulos D, Kiroudi A, Mitsogiannis I, Costomitsopoulos N, Kittas C, Karayannacos P, Dimopoulos C (1999) In vivo effect of the lipido-sterolic extract of Serenoa repens (Permixon) on mast cells accumulation and glandular epithelium trophism in the rat prostate (abstract). J Urol 161 [Suppl]: 362
86. Thomas JA, Keenan EJ (1976) Prolactin influences upon androgen action in male accessory sex organs. Adv Sex Hormone Res 2: 425-470
87. Vacher P, Prevarskaya N, Skryma R Audy MC, Vacher AM, Odessa MF, Dufy B (1995) The lipidosterolic extract from Serenoa repens interferes with prolactin receptor signal transduction. J Biomed Sci 2: 357-365
88. 14C-qsitosterol]. Eur J Drug Metab Pharmacokinet 22: 1-10